Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord MSCs for Severe COVID-19 (CELMA)
NCT04429763Phase 2Unknown
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Composite of clinical deterioration or death at 4 weeks. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04429763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429763.